title: New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
abstract: The purpose of this review is to evaluate the efficacy and safety of ceftazidime/avibactam and ceftolozane/tazobactam in patients with complicated intra-abdominal infections (cIAI), and review eravacycline and other agents in the pipeline for management of cIAI. The increasing incidence of multidrug resistant strains of bacteria has led to the need for additional antibiotics with activity against these organisms. There are 2 newly approved antibiotics, ceftazidime/avibactam and ceftolazane/tazobactam for treatment of cIAI. Both agents have been shown to exert activity against resistant bacteria, including extended-spectrum beta-lactamase-producing organisms. Several other antibiotics are currently under investigation for this indication. Included in the pipeline of agents is a new tetracycline, an aminoglycoside, 2 new fluroquinolones, and 2 new beta-lactamase inhibitor combinations with carbapenems. Although the mechanisms for these new agents are not novel, promising data have shown their ability to overcome class resistance. The passing of the Generating Antibiotic Incentives Now Act has led to an increasing number of fast tracked antibiotic approvals. In addition to recent approval of ceftazidime/avibactam and ceftolazane/tazobactam, several other emerging antibiotics are under investigation which will aid in the management of resistant cIAI.
authors.affiliation: 1Department of Pharmacy Practice, School of Pharmacy-Worcester/Manchester, MCPHS University, Manchester, NH; and 2Department of Pharmacy, PGY-1 Pharmacy Practice Resident, University of North Carolina Hospitals, Chapel Hill, NC.
authors.forename: Cheryl R
authors.initials: CR
authors.lastname: Durand
authors.forename: Mohammad
authors.initials: M
authors.lastname: Alsharhan
authors.forename: Kristine C
authors.initials: KC
authors.lastname: Willett
mesh_terms: D053961:Azabicyclo Compounds / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods / Q000639:trends; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy* / Q000382:microbiology; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078142:Tazobactam; D013754:Tetracyclines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D053961:Azabicyclo Compounds; D002511:Cephalosporins; D004338:Drug Combinations; D013754:Tetracyclines; C000595613:avibactam, ceftazidime drug combination; C000594038:ceftolozane, tazobactam drug combination; C571179:eravacycline; D010397:Penicillanic Acid; D002442:Ceftazidime; D000078142:Tazobactam